Molecular Partners Ag (MOLN) Times Interest Earned (2020 - 2026)
Molecular Partners Ag's (MOLN) quarterly Times Interest Earned came in at 1.24 in Q2 2026, up 24879.18% year-over-year from N/an in Q2 2025, and up 1.1% quarter-over-quarter from 1.22 in Q1 2026.
Analysis
Molecular Partners Ag (MOLN) Times Interest Earned (2020 - 2026) Analysis & Trends
Molecular Partners Ag (MOLN) has reported Times Interest Earned for 7 consecutive years, with 1.24 the latest figure, recorded in Q2 2026.
- On a quarterly basis, Times Interest Earned rose 24879.18% year-over-year to 1.24 in Q2 2026; TTM through Jun 2026 was 133.18, a 1705.51% increase from a year earlier, with the FY2025 full-year figure at 11.51, up 100.71% from the prior year.
- Times Interest Earned was 1.24 for Q2 2026 at Molecular Partners Ag, up from 1.22 in the prior quarter.
- Over five years, Times Interest Earned peaked at 887.56 in Q2 2024 and troughed at 9706.79 in Q4 2022.
- A 5-year average of 852.14 and a median of 0.92 in 2022 frame the typical range for Times Interest Earned.
- Across the five-year window, Times Interest Earned sank 47641.96% in 2024 and surged 24879.18% in 2026, its largest moves.
- Over 5 years, Times Interest Earned stood at 9706.79 in 2022, then soared by 100.15% to 14.31 in 2023, then slumped by 47641.96% to 6805.16 in 2024, then soared by 103.32% to 225.89 in 2025, then tumbled by 99.45% to 1.24 in 2026.
- The last three Times Interest Earned figures came in at 1.24 (Q2 2026), 1.22 (Q1 2026), and 225.89 (Q4 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Times Interest Earned (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 206.44 Bn | 192.45 Bn | 7.24 Bn | 5.22 |
| 2 | Gilead Sciences | 179.97 Bn | 176.79 Bn | 6.22 Bn | -42.08 |
| 3 | Vertex Pharmaceuticals | 130.57 Bn | 122.72 Bn | 2.84 Bn | - |
| 4 | Regeneron Pharmaceuticals | 81.63 Bn | 73.63 Bn | 3.93 Bn | 117.59 |
| 5 | Argenx Se | 60.34 Bn | 55.16 Bn | 1.37 Bn | 493.00 |
| 6 | Moderna | 54.37 Bn | 49.23 Bn | 52.00 Mn | - |
| 7 | Alnylam Pharmaceuticals | 33.07 Bn | 29.76 Bn | 992.69 Mn | 2.82 |
| 8 | Biogen | 31.84 Bn | 30.55 Bn | 1.96 Bn | - |
| 9 | Roivant Sciences | 29.49 Bn | 29.49 Bn | 1.16 Mn | - |
| 10 | Molecular Partners Ag | 156.54 Mn | 156.54 Mn | - | -1,235.55 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 1.24 |
| Mar 31, 2026 | 1.22 |
| Dec 31, 2025 | 225.89 |
| Sep 30, 2025 | 0.08 |
| Jun 30, 2025 | 0.00 |
| Mar 31, 2025 | 0.01 |
| Dec 31, 2024 | -6,805.16 |
| Sep 30, 2024 | 0.01 |
| Jun 30, 2024 | 887.56 |
| Mar 31, 2024 | 1.59 |
| Dec 31, 2023 | 14.31 |
| Sep 30, 2023 | 1.23 |
| Jun 30, 2023 | 13.32 |
| Mar 31, 2023 | 0.03 |
| Dec 31, 2022 | -9,706.79 |
| Sep 30, 2022 | 0.13 |
| Jun 30, 2022 | 26.11 |
| Mar 31, 2022 | 0.61 |
| Dec 31, 2021 | 597.83 |
| Sep 30, 2021 | 0.10 |